According to data developed by our sister organization, ChinaBio® Consulting, there were more M&A deals in China biopharma during the first 10 months of 2008 than in all of 2007.  The dollar value is also higher this year. However, the average deal size has dropped from $41.7 million last year to $25 million in 2008.  More details...

Stock Symbols: (NYSE: WX) (NYSE: MR) (NSDQ: DSCP)